Skip to main content
    S

    SAB Biotherapeutics Inc (SABS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.00
    +0.04 (+1.35%)

    Market Cap: $266.66M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    SAB Biotherapeutics Inc (SABS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    SAB Biotherapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025, down 100.0% from the year before. That year, net income was $13.27M, operating cash flow was -$44.78M and free cash flow was -$45.71M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$22.30M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $48.95M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0-100.0%N/AN/AN/A
    Dec 2024$1.32M-40.9%100.0%-3244.9%-2579.0%
    Dec 2023$2.24M-90.6%100.0%-1700.6%-1884.5%
    Dec 2022$23.90M-60.7%100.0%-121.0%-78.4%
    Dec 2021$60.88M+10.2%100.0%-22.0%-28.2%
    Dec 2020$55.24M+1504.8%100.0%37.2%36.4%
    Dec 2019$3.44MN/A100.0%-252.0%-261.1%
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$0$1.32M$2.24M$23.90M$60.88M$55.24M$3.44M
    Gross profit$0$1.32M$2.24M$23.90M$60.88M$55.24M$3.44M
    Research and development$34.35M$30.25M$16.52M$36.44M$57.18M$27.91M$8.02M
    Operating income-$48.95M-$42.91M-$38.08M-$28.92M-$13.39M$20.56M-$8.67M
    Net income$13.27M-$34.11M-$42.19M-$18.74M-$17.14M$20.12M-$8.99M
    EBITDA$15.08M-$30.52MN/A-$15.19MN/A$21.10M-$8.23M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$114.70K$0$263.14K$944.58K$305.01K
    Gross profit$0$0$0-$763.30K$0$0$0$114.70K$0$263.14K$944.58K$305.01K
    Operating income-$25.90M-$23.38M-$20.00M-$15.77M-$12.68M-$9.73M-$10.77M-$10.01M-$11.31M-$10.20M-$11.39M-$18.87M
    Net income-$22.30M-$22.49M-$18.87M-$16.86M$45.45M-$10.11M-$5.20M-$11.39M-$10.35M-$7.34M-$5.03M-$22.86M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $0 by $10.50M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$172.81M$44.20M$83.94M$50.90M$81.14M$56.54M$18.00M
    Current assets$101.05M$23.79M$58.91M$22.10M$50.19M$34.46M$9.29M
    Cash and equivalents$10.50M$8.90M$56.57M$15.05M$33.21M$12.61M$6.35M
    Total liabilities$21.32M$18.23M$26.64M$19.85M$42.59M$17.53M$20.31M
    Short-term debt$0$275.85K$1.05M$772.66K$1.80M$538.73K$1.95M
    Long-term debtN/AN/AN/A$541.64K$0$172.04K$53.45K
    Shareholder equity$151.50M$25.97M$57.30M$31.06M$38.55M$39.01M-$2.31M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$235.64M$238.21M$248.47M$172.81M$183.45M$30.13M$38.12M$44.20M$53.80M$61.89M$71.37M$83.94M
    Total liabilities$24.72M$23.43M$21.22M$21.32M$18.37M$18.11M$16.71M$18.23M$16.89M$15.77M$18.55M$26.64M
    Cash and equivalents$14.44M$8.27M$20.52M$10.50M$29.42M$3.69M$5.64M$8.90M$9.17M$17.24M$14.03M$56.57M
    Shareholder equity$210.92M$214.78M$227.25M$151.49M$165.07M$12.02M$21.41M$25.97M$36.90M$46.12M$52.82M$57.30M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$44.78M-$34.29M-$25.12M-$23.46M$1.99M$10.00M-$9.21M
    Capital expenditures$933.16K$337.26K$197.15K$2.17M$10.94M$12.73M$608.75K
    Free cash flow-$45.71M-$34.63M-$25.32M-$25.63M-$8.96M-$2.73M-$9.82M
    Investing cash flow-$121.71M-$11.96M-$152.70K-$2.09M-$10.94M-$12.72M-$608.75K
    Financing cash flow$168.30M-$1.17M$66.77M$1.05M$35.89M$8.98M$3.68M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$13.02M-$9.84M-$14.27M-$16.78M-$13.05M-$7.15M-$7.80M-$9.53M-$6.29M-$7.72M-$10.75M-$13.45M
    Capital expenditures$1.34M$1.59M$983.26K$933.16K$3$4$0$55.38K$100.30K$52.51K$129.07K$67.86K
    Free cash flow-$14.37M-$11.43M-$15.25M-$17.71M-$13.05M-$7.15M-$7.80M-$9.59M-$6.39M-$7.77M-$10.88M-$13.51M
    Last 12 quarters

    Frequently Asked Questions About SABS

    What is SAB Biotherapeutics' annual revenue?

    SAB Biotherapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    How fast is SAB Biotherapeutics' revenue growing?

    Revenue was down 100.0% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is SAB Biotherapeutics profitable?

    Yes. SAB Biotherapeutics reported net income of $13.27M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does SABS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$44.78M minus capital expenditures of $933.16K produced free cash flow of -$45.71M.

    How much debt does SAB Biotherapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $0 and cash and equivalents of $10.50M.